Oral administration of AZD0530 at dosages of 10 mg/kg and 20 mg/kg effectively reduced the number of inflammatory cells, the percentage of neutrophils, and the levels of IL-1β and TNF-α in COPD model rats (Figure 3C-3F, P<0.05). Here, TNF is linked to chronic obstructive pulmonary disease.